Jill Shuman: Ledger

Stories naming Jill Shuman. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
No role recorded yet. Jill Shuman has been mentioned, but not yet attached to an organisation. Know their role?

Series A US$20.5m

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend has begun a Phase 1 trial in South Australia for its oral polymer diabetes therapy and presented preclinical data; its US$20.5 million Series A was led by Santé Ventures and Brandon Capital.

Brandon BioCatalyst portfolio 29 Sep 2021 Glyscend, Inc.Glyscend Johns Hopkins University Medical Research Commercialisation Fund Thiel Foundation Brandon Capital Breakout Labs Santé Ventures Ashish Nimgaonkar Chris Rayner Jill Shuman Michael Horowitz Thomas Jozefiak

Jill Shuman

Roles

Coverage

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy